Opus Genetics is a clinical-stage company advancing AAV gene therapies designed to treat inherited retinal diseases by correcting the underlying genetic defects. Its development programs target several specific mutations, including those responsible for LCA5-related Leber congenital amaurosis and BEST1-related retinal degeneration, with the aim of providing long-lasting vision restoration through single treatments. The pipeline addresses rare ophthalmic conditions that currently have limited therapeutic options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2.9 | — | -7.4 | — |
| Q3 2025 | 3.1 | — | -17.4 | — |
| Q4 2025 | 3.9 | — | -16.5 | — |
| Q1 2026 | 2.2 | — | -65.5 | — |
| Q2 2026 | 0.8 | -73.8% | -8.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Forafric Global PLC (AFRI), Range Capital Acquisition Corp II (RNGT), Cantor Equity Partners VII, Inc. (CAES), NewtekOne, Inc. (NEWT), Eightco Holdings Inc. (ORBS), BTQ Technologies Corp. (BTQ)